Trial intelligence / Profile preview

MK-8457 versus placebo in active rheumatoid arthritis on background methotrexate

ACTRN12612000774820Phase 2Terminated

Sponsor
MSD
Start
Jan 2013
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
Countries
2
01

Overview

Phase 2, randomised trial in rheumatoid arthritis (RA) comparing MK-8457 plus methotrexate with Placebo plus methotrexate (2 arms). Primary endpoints: ACR20 response at Week 12 and Safety and tolerability over 12 weeks. Started Jan 2013; status: terminated.

02

Drugs

MK-8457
03

Conditions

rheumatoid arthritis (RA)

Beyond the preview

Go deeper on ACTRN12612000774820.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on ACTRN12612000774820.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call